Compare IPST & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPST | NXTS |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | Israel |
| Employees | 21 | 9 |
| Industry | Beverages (Production/Distribution) | Agricultural Chemicals |
| Sector | Consumer Staples | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.6M |
| IPO Year | N/A | N/A |
| Metric | IPST | NXTS |
|---|---|---|
| Price | $4.81 | $5.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $164.00 | N/A |
| AVG Volume (30 Days) | ★ 99.5K | 39.0K |
| Earning Date | 04-14-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $70.16 | N/A |
| Revenue Next Year | $60.33 | N/A |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.55 |
| 52 Week High | $15.08 | $6.25 |
| Indicator | IPST | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | 65.71 |
| Support Level | $0.61 | $3.97 |
| Resistance Level | $6.71 | $6.23 |
| Average True Range (ATR) | 1.40 | 0.71 |
| MACD | -0.41 | -0.00 |
| Stochastic Oscillator | 18.73 | 65.20 |
IP Strategy Holdings Inc operate a diversified business centered on digital asset-based infrastructure and intellectual property (IP) management, supplemented by a legacy craft spirits operating segment. The Company provides public market investors with broad exposure to the around $80 trillion programmable intellectual property economy in a regulated equity format. Its treasury reserve of $IP tokens provides direct participation in the Story ecosystem, which enables on-chain registration, licensing, and monetization of intellectual property.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.